The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials

Obesity Reviews

Volumn 17, Issue 12, 2016, Pages 1329-1340

  Huang, Haohai ^a   Chen, Guangzhao ^b   Liao, Dan ^c   Zhu, Yongkun ^a   Pu, Rong ^a   Xue, Xiaoyan ^a  

^a Affiliated Dongguan Shilong People's Hospital of Southern Medical University   (China)

^b Guangdong Province Agricultural Reclamation Central Hospital   (China)

^c Dongguan Maternal and Child Health Hospital   (China)

Author keywords

Cardiovascular risk factors; obesity; overweight; resveratrol

Indexed keywords

CHOLESTEROL; GLUCOSE; INSULIN; RESVERATROL; BIOLOGICAL MARKER; STILBENE DERIVATIVE;

BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECT SIZE; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LEUKOPENIA; LOOSE FECES; OBESITY; REVIEW; SYSTOLIC BLOOD PRESSURE; THROMBOCYTOPENIA; BLOOD; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASES; DRUG EFFECTS; INSULIN RESISTANCE; META ANALYSIS (TOPIC); OVERWEIGHT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; RISK FACTOR;

BIOMARKERS; BLOOD PRESSURE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL; HUMANS; INSULIN RESISTANCE; META-ANALYSIS AS TOPIC; OBESITY; OVERWEIGHT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STILBENES;

EID: 84979255701     PISSN: 14677881     EISSN: 1467789X     Source Type: Journal    
DOI: 10.1111/obr.12458     Document Type: Review

References (47)

1. WHO. (2016). Obesity and overweight: fact sheet World Health Organ isation. Available at: http://www.who.int/mediacentre/factsheets/fs311/en/.
2. Manson JE, Skerrett PJ, Greenland P, VanItallie TB. The escalating pandemics of obesity and sedentary lifestyle. A call to action for clinicians. Arch Intern Med 2004; 164: 249–58.
3. Ashraf MJ, Baweja P. Obesity: the ‘huge’ problem in cardiovascular diseases. Mo Med 2013; 110: 499–504.
4. Georgousopoulou EN, Panagiotakos DB, Pitsavos C, Stefanadis C. Assessment of diet quality improves the classification ability of cardiovascular risk score in predicting future events: the 10-year follow-up of the ATTICA study (2002–2012). Eur J Prev Cardiolog 2015; 22: 1488–98.
5. Rivellese AA. Diet and cardiovascular disease: beyond cholesterol. Nutr Metab Cardiovasc Dis 2005; 15: 395–8.
6. Brunner EJ, Rees K, Ward K, Burke M, Thorogood M. Dietary advice for reducing cardiovascular risk. Cochrane Database Syst Rev 2007: CD002128.
7. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493–506.
8. Das M, Das DK. Resveratrol and cardiovascular health. Mol Aspects Med 2010; 31: 503–12.
9. Tome-Carneiro J, Gonzalvez M, Larrosa M et al. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann N Y Acad Sci 2013; 1290: 37–51.
10. Higgins JP, Green S. (2011). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011). Available at: http://handbook.cochrane.org/.
11. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009; 6: e1000100.
12. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557–60.
13. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–34.
14. Fujitaka K, Otani H, Jo F et al. Modified resveratrol Longevinex improves endothelial function in adults with metabolic syndrome receiving standard treatment. Nutr Res 2011; 31: 842–7.
15. Timmers S, Konings E, Bilet L et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612–22.
16. Tome-Carneiro J, Gonzalvez M, Larrosa M et al. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2013; 27: 37–48.
17. Tome-Carneiro J, Gonzalvez M, Larrosa M et al. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am J Cardiol 2012; 110: 356–63.
18. Magyar K, Halmosi R, Palfi A et al. Cardioprotection by resveratrol: a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50: 179–87.
19. Wong RH, Berry NM, Coates AM et al. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens 2013; 31: 1819–27.
20. Movahed A, Nabipour I, Lieben Louis X et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013; 2013: 851267.
21. Dash S, Xiao C, Morgantini C, Szeto L, Lewis GF. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler Thromb Vasc Biol 2013; 33: 2895–901.
22. Poulsen MM, Vestergaard PF, Clasen BF et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013; 62: 1186–95.
23. Mendez-del Villar M, Gonzalez-Ortiz M, Martinez-Abundis E, Perez-Rubio KG, Lizarraga-Valdez R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord 2014; 12: 497–501.
24. Chachay VS, Macdonald GA, Martin JH et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014; 12: 2092–103 e1-6.
25. Witte AV, Kerti L, Margulies DS, Floel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci 2014; 34: 7862–70.
26. Anton SD, Embry C, Marsiske M et al. Safety and metabolic outcomes of resveratrol supplementation in older adults: results of a twelve-week, placebo-controlled pilot study. Exp Gerontol 2014; 57: 181–7.
27. Bashmakov YK, Assaad-Khalil SH, Abou Seif M et al. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN endocrinology 2014; 2014: 816307.
28. Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr 2015; 114: 796–803.
29. Chen S, Zhao X, Ran L et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis 2015; 47: 226–32.
30. Gliemann L, Schmidt JF, Olesen J et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J Physiol 2013; 591: 5047–59.
31. van der Made SM, Plat J, Mensink RP. Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial. PLoS One 2015; 10: e0118393.
32. Heeboll S, Kreuzfeldt M, Hamilton-Dutoit S et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol 2016; 51: 456–64.
33. Thazhath SS, Wu T, Bound MJ et al. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. Am J Clin Nutr 2016; 103: 66–70.
34. Liu K, Zhou R, Wang B, Mi MT. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2014; 99: 1510–9.
35. Hausenblas HA, Schoulda JA, Smoliga JM. Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. Mol Nutr Food Res 2015; 59: 147–59.
36. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2015; 34: 27–34.
37. Zambon A. Residual cardiovascular risk in secondary prevention. Intern Emerg Med 2011; 6: 61–8.
38. Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769–818.
39. Siegel E, Kellerer M. The clinical practice recommendations of the German Diabetes Association. Exp Clin Endocrinol Diabetes 2014; 122: 383.
40. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130–1.
41. Liu Z, Song Y, Zhang X et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 2005; 32: 1049–54.
42. Miatello R, Vazquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18: 864–70.
43. Chi TC, Chen WP, Chi TL et al. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci 2007; 80: 1713–20.
44. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150: 5326–33.
45. de Heredia FP, Gomez-Martinez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332–8.
46. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol 2012; 302: H2148–65.
47. Herder C, Karakas M, Koenig W. Biomarkers for the prediction of type 2 diabetes and cardiovascular disease. Clin Pharmacol Ther 2011; 90: 52–66.